Novo Nordisk

Rybelsus has now been expanded to treat those at high risk of heart attack and stroke

Diabetes

First oral GLP-1 cuts cardiovascular risk by 14% – and it's now FDA-approved

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of cardiovascular events like heart attack and stroke.

Novo Nordisk has not one but three new and distinct weight loss therapeutics

Obesity

Ozempic maker announces not one, but three new weight-loss drugs

Over the weekend, Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from the pharmaceutical giant.

This time next year, you may be swapping GLP-1 injections for oral medication i

Obesity

Breakthrough weight-loss pill expected to launch within 12 months

The first once-daily oral GLP-1 medication could be on shelves by this time next year, making the weight-loss drug easier to take and potentially cheaper. In the race to be the first, Novo Nordisk has scored a huge win, while Pfizer has failed again.